Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
Table of Contents

until May 2003. Mr. McKinney also previously held several roles at Texas Biotechnology in Houston from March 1994 to April 2000, where he most recently served as Head of Strategic Planning. Mr. McKinney earned his B.S. degree in Microbiology from the University of Oklahoma and his M.B.A. from Thunderbird, the Garvin School of International Management.
 
Graham K. Cooper has served as our Chief Financial Officer, Treasurer and Secretary since May 2006. Previously, Mr. Cooper held the position of Director, Health Care Investment Banking at Deutsche Bank Securities. During his tenure from August 1997 to February 2006 at Deutsche Bank and its predecessor firm Alex. Brown & Sons, he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From August 1992 to January 1995, he worked as an accountant at Deloitte & Touche, where he earned his C.P.A. Mr. Cooper received a B.A. in Economics with highest distinction from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
 
Michael A. Cowley, Ph.D. is one of our co-founders and has served as our Chief Scientific Officer since November 2006. Dr. Cowley is a scientist in the Division of Neuroscience at the Oregon National Primate Research Center of the Oregon Health & Science University where he is also director of the Electrophysiology Core, which positions he has held since December 2001. Research in Dr. Cowley’s lab has focused on the discovery of signals within the body that regulate energy balance, as well as describing how other known signals exert their effects on the brain. Research in the lab now focuses on how these signals from the body change with obesity and how the reward based pathways overrule homeostatic signals of satiety. Dr. Cowley received a B.Sc. in biochemistry from The University of Melbourne and a Ph.D. in reproductive neuroendocrinology from Monash University.
 
Eduardo Dunayevich, M.D. has served as our Chief Medical Officer since August 2006. Previously, Dr. Dunayevich spent five years with Lilly Research Laboratories where most recently he was a Medical Advisor in the Clinical Neuroscience Program Phase, a position he held from January 2005 to August 2006. At Lilly Research Laboratories, he was responsible for the development of several early phase compounds, overseeing protocol development, clinical trial implementation, data analysis and reporting and adherence to good clinical practice standards. Prior to joining Lilly Research Laboratories, Dr. Dunayevich served as Director of the Clinical Psychobiology Program, Psychobiology Inpatient Unit and Division of Clinical Trials of the Psychotic Disorders Research Program at the University of Cincinnati, a position he held from July 1998 to June 2001. Dr. Dunayevich obtained his M.D. from the Buenos Aires Medical School where he graduated with honors and received residency training in psychiatry at both the Hospital of the Italian Community, Buenos Aires, Argentina and the University of Cincinnati Medical Center.
 
Ronald P. Landbloom, M.D. has served as our Vice President of Medical and Regulatory Affairs since September 2006. Previously, Dr. Landbloom spent over four years with Eli Lilly, where he was the Associate Medical Director for Neuroscience in their U.S. affiliate organization from April 2005 to October 2006. Prior to joining Eli Lilly, Dr. Landbloom had over 20 years of clinical, research and teaching experience within the University of Minnesota affiliated teaching programs, where he served from 1981 to March 2002. He has also held administrative positions while in the U.S. Army Medical Corp. and at several major healthcare institutions including HealthPartners Medical Group and Clinics, and Regions Hospital in Saint Paul, Minnesota. Dr. Landbloom has been the principal investigator on over 80 different research projects in the fields of depression, schizophrenia, dementia, Alzheimer’s disease and obsessive compulsive disorder. Dr. Landbloom earned his B.S. degree from the University of New Mexico and his M.D. from the University of Minnesota, where he also completed his residency in psychiatry.
 
Franklin P. Bymaster has served as our Vice President of Neuroscience since September 2006. Previously, Mr. Bymaster spent more than 30 years as a leading biochemist for Eli Lilly, culminating in his position as the Biochemistry Scientific Leader of the Neuroscience Division and Senior Research Scientist, a position he held from December 1999 to December 2003. At Eli Lilly, Mr. Bymaster made significant contributions in several marketed compounds such as Prozac, Permax, Zyprexa, Strattera, Cymbalta and Symbyax. He has been involved with more than 40 patents, over 45 IND reports, and has published over 160 papers in the field of pharmacology. Since retiring from Eli Lilly in 2003, he became a research


91